Announcements
- Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
- Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
- Akero Therapeutics Announces Pricing of Public Offering of Common Stock
- Akero Therapeutics Announces Proposed Public Offering of Common Stock
- Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
- Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
- Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
More ▼
Key statistics
As of last trade, Akero Therapeutics Inc (0K4:DUS) traded at 20.42, 92.64% above the 52 week low of 10.60 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 20.39 |
---|---|
High | 20.42 |
Low | 20.39 |
Bid | 20.38 |
Offer | 20.71 |
Previous close | 19.72 |
Average volume | 0.00 |
---|---|
Shares outstanding | 69.15m |
Free float | 59.01m |
P/E (TTM) | -- |
Market cap | 1.53bn USD |
EPS (TTM) | -2.85 USD |
Data delayed at least 15 minutes, as of May 07 2024 11:30 BST.
More ▼